We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at ...

Biohaven Ltd. will present an investor presentation detailing its ongoing and planned trials for various development programs, including troriluzole, taldefgrobep ...

Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...

Biohaven (NYSE:BHVN) stock gains on tumor-shrinking results for the company's cancer drug BHV-1510 with Regeneron's (REGN) ...

NEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to ...

Biohaven Pharmaceutical BHVN and Pfizer PFE announced a definitive agreement wherein the latter will acquire the former for $148.50 per share or an aggregate equity value of $11.6 billion.

Biohaven Rallies On Heels Of $600M Funding Agreement With Oberland Biohaven Ltd. (BHVN) shares rise premarket as it secures up to $600 million investment from Oberland Capital. Cash reserves ...

BHVN’s lead asset is Troriluzole, which is nearing a pivotal FDA decision by August 2025. The company also recently secured an additional $600 million financing through secured notes with ...

In trading on Thursday, shares of Biohaven Ltd (Symbol: BHVN) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $28.47 per share. By comparison ...

Investors in Biohaven Pharmaceutical Holding Co Ltd (Symbol: BHVN) saw new options become available this week, for the June 17th expiration. At Stock Options Channel, our YieldBoost formula has ...